The FY17 Defense Appropriations Act provides $16 million (M) to the Department of Defense Parkinson’s Research Program (PRP), formerly the Neurotoxin Exposure Treatment Parkinson’s Research Program, to support research of exceptional scientific merit leading to an understanding of the cause, prevention, and treatment of the loss of dopaminergic neurons in the substantia nigra that result in Parkinson’s disease.  Applications to the FY17 PRP are being solicited by the U.S. Army Medical Research Acquisition Activity.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY17 PRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

IMPORTANT:  The PRP seeks to focus applications and direct funding by providing Focus Areas to address the critical needs in Parkinson’s disease research.  Applications to the FY17 PRP must address at least one of the Focus Areas noted below: 

• Mechanisms of neuroplasticity in the Parkinson’s disease brain
• Studies to identify gene-environment interactions in Parkinson’s disease cohorts
• Pathophysiological implications of tau protein in Parkinson’s disease

Investigator-Initiated Research Award – Letter of Intent due August 17, 2017

Independent investigators at or above the level of Assistant Professor (or equivalent).

·         Supports highly rigorous, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research and/or patient care.

·         Potential impact of research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.

·         Clinical trials are not allowed.

·         Preliminary data to support feasibility are encouraged.

·         Partnering PI Option:

·         Provides a higher level of funding to support synergistic partnerships between two or three independent investigators collaborating on a single application.

• ·         Principal Investigators (PIs) are expected to demonstrate within the application the synergistic components that will significantly advance the project, such that the research outcomes could not otherwise be accomplished through the independent efforts of a single PI.

·         Individual PI:

·         Maximum funding of $1M in total costs.

·         Maximum period of performance is 3 years.

·         Partnering PI Option:

·         Maximum funding of $2.5M in total costs.

·         Maximum period of performance is 4 years.

 

Early Investigator Research Award – Letter of Intent due August 17, 2017

Investigator must be a postdoctoral or clinical fellow within 3 years of advanced degree or residency training (or equivalent).

Verification of eligibility criteria must be provided in an Eligibility Statement signed by an appropriate institutional official and the PI. 

·         Supports early-career investigators who have innovative, high-impact ideas or new technologies applicable to Parkinson’s disease research and/or patient care.

·         Clinical fellows must be specialized in movement disorders.

·         PIs must have a designated mentor who is an experienced Parkinson’s disease researcher.

·         The application must include an individualized, Parkinson’s disease-focused researcher development plan.

·         Preliminary data are not required.

• ·         Clinical trials are not allowed.

·         Maximum funding of $321,000 in total costs.

• ·         Maximum period of performance is 2 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507
help@eBrap.org

FY17 ARP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) Research and Development Directorate (J9) manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

Clinical Trial Award – Preapplication due July 2, 2017

Investigators at or above the level of Associate Professor (or equivalent), or

• ·         Early-Career Investigator Option:
  Investigators at or above the level of Associate Professor (or equivalent) may collaborate on a single application with a Early-Career Investigator (at the level of postdoctoral fellow up to early-career independent faculty) that meets the following criteria at the application submission deadline date:
• o    Must be within the first year of postdoctoral fellowship by the application deadline
• o    Is no more than 7 years from the receipt of a terminal degree
• o    Has the freedom to commit at least 50% time to the project
• ·         Supports research with the potential to have a major impact on the treatment and/or management of autism spectrum disorder (ASD).
• ·         Applications in the following areas are strongly encouraged:
• o    Behavioral, cognitive, and other non-pharmacological therapies.  Studies targeting subgroups using biomarkers with preliminary data are strongly encouraged.
• o    Pharmacological treatments in ASD. Studies targeting subgroups using biomarkers with preliminary data are strongly encouraged.
• o    Dissemination/implementation of clinically validated interventions across the lifespan.
• o    Therapies to alleviate conditions co-occurring with ASD.
• o    Interventions promoting success in ley transitions to adulthood for individuals living with ASD.
• o    Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD, particularly adulthood.

• Preliminary data relevant to the proposed project are required.
• Pre-application is required; application submission is by invitation only.

 

• ·         Nested Early-Career Investigator Option supports the development of young investigators pursuing or wishing to pursue clinical trials.

• Maximum funding of $1,000,000 for direct costs (plus indirect costs)
• Maximum period of performance is 4 years

 

• ·         Nested Yearly-Career  Investigator Option:

• Maximum funding of $1,300,000 for direct costs (plus indirect costs)

• ·         Maximum period of performance is 4 years

 

Idea Development Award – Preapplication due July 26, 2017

Investigators at or above the level of Assistant Professor (or equivalent)

• ·         Supports the development of innovation, high-impact ideas that advance the understanding of ASD and ultimately lead to improved outcomes.
• ·         Applications in the following areas are strongly encouraged:
• o    Assessment of novel therapeutics using valid preclinical models.
• o    Environmental risk factors.
• o    Mechanisms of heterogeneous clinical expression of ASD.
• o    Factors promoting success in key transitions to independence for individuals living with ASD.
• o    Development of healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD, particularly in adulthood.
• o    Cultural factors in treatment efficacy, delivery, and access to services.

• Preliminary data are required.

• ·         Pre-application is required; application submission is by invitation only.

• Multiple Principal Investigator (PI) Option: Up to two investigators may collaborate on a single application, each of whom will be recognized as a PI and receive a separate award.
• Maximum allowable funding for the entire period of performance is of $500,000 in direct costs
• For multiple PI’s the combined funding for all PIs for the entire period of performance may not exceed $500,000 in direct costs.
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• Maximum period of performance is 3 years

 

Clinical Translational Research Award – Preapplication due July 26, 2017

Investigators at or above the level of Assistant Professor (or equivalent)

• Supports early-phase, proof-of-principle translational studies with the potential to have a major impact on the treatment and/or management of ASD.
• Applications in the following areas are strongly encouraged:
• • Behavioral, cognitive, and other non-pharmacological therapies.  Studies targeting subgroups using biomarkers with preliminary date are strongly encouraged.
  • Pharmacological treatments in ASD.  Studies targeting subgroups using biomarkers with preliminary data are strongly encouraged.
  • Dissemination/implementation of clinically validated interventions across the lifespan.
  • Therapies to alleviate conditions co-occurring with ASD.
  • Healthcare provider-focused training or tools to improve healthcare delivery for individuals with ASD, particularly in adulthood.
• Preliminary data relevant to the proposed project are required.

• ·         Pre-application is required; application submission is by invitation only.

• The maximum allowable funding for the entire period of performance is $500,000 in direct costs
• Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

• ·         Maximum period of performance is 3 years

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the federal government’s single-entry portal, Grants.gov. For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the ARP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507

help@eBrap.org

The FY17 Defense Appropriations Act provides $8 million (M) to the Department of Defense MBRP to support a broad research portfolio in the treatment of burns and the trauma associated with burn injuries sustained during combat or combat-related activities.  Applications to the FY17 MBRP are being solicited by the U.S. Army Medical Research Acquisition Activity.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY17 MBRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

To be considered for funding, each application for the FY17 MBRP Clinical Trial Award must address the following Topic Area: 

Clinical studies that involve the prevention, treatment, and mitigation of debilitating burn scars (e.g., dressing topics, biologics, cell-based therapies, mechanical, photonics, etc.) to improve functional outcomes and/or assess clinical efficacy and safety of different treatment modalities.

 

Clinical Trial Award – Preproposal due August 3, 2017

• ·         Independent investigators at all academic levels (or equivalent) are eligible to submit applications.

• Research Level 1:  This level will support early-stage clinical trials (i.e., proof-of-concept, pilot, first-in-human, or Phase 0) to address the Topic Area.
• Research Level 2:  This level will support Phase I and/or Phase II multi-center clinical trials that address the Topic Area and assess the clinical efficacy and safety of different treatment modalities.
• Funding must support a clinical trial and may not be used for preclinical studies.

• ·         Inclusion of preliminary data relevant to the proposed clinical trial is required.
• ·         Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 6 months of the award date.

·         For Research Level 1

·         Maximum funding of $1.75M for total costs (direct and indirect).

·         Maximum period of performance is 4 years.

• ·         For Research Level 2

·         Maximum funding of $3.5M for total costs (direct and indirect).

• ·         Maximum period of performance is 4 years.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the MBRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBRap.org

The FY17 Defense Appropriations Act provides $15 million (M) to the Department of Defense NFRP to support innovative, high-impact NF research.  Applications to the FY17 NFRP are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA). The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

FY17 NFRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Areas of Emphasis:  The NFRP encourages applications that specifically address the critical needs of the NF community in one or more of the FY17 Areas of Emphasis.  Not all Areas of Emphasis are applicable to each award mechanism offered by the FY17 NFRP.  If the proposed research project does not address one of the FY17 Areas of Emphasis, justification that the proposed research project addresses an important problem related to NF research and/or patient care should be provided.

Health services research

·         Evidence-based clinical care pathways

·         Innovative healthcare delivery systems

·         Utilization of technology and informatics

Heterogeneity of neurofibromas and other NF-related tumors

Nontumor manifestations

·         Sleep, pain, hypotonia, communication, etc., including quality of life measures, self-reported and otherwise

Novel disease and treatment response markers using genomics, epigenetics, systems biology, metabolomics, or similar approaches

·         Transition from benign to malignant

Nutritional, environmental, and other modifiers of NF

Post-adolescent manifestations

Preclinical efficacy studies

Target identification, drug discovery, targeted and immunotherapies

Other

 

Clinical Trial Award – Letter of Intent due Jul7 26, 2017

• ·         Independent investigators at or above the level of Assistant Professor (or equivalent)
• ·         Fund Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis; combinations of phases are permitted.
• ·         Funding must support a clinical trial and may not be used for preclinical studies.
• ·         Scientific rationale and preliminary data required for Phase I, II clinical trial applications.

·         Maximum funding of $900,000 for direct costs (plus indirect costs)

• ·         Maximum period of performance is 4 years
• ·          

Exploration – Hypothesis Development Award – Letter of Intent due July 26, 2017

• ·         All academic levels (or equivalent)

·         Fund the initial exploration of innovative, high-risk, high-gain and potentially. groundbreaking concepts in NF research

·         Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.

·         Preliminary and/or published data is encouraged but not required.

• ·         Clinical trials not allowed

·         Maximum funding of $100,000 for direct costs (plus indirect costs)

• ·         Maximum period of performance is 2 years

 

Investigator-Initiated Research Award – Letter of Intent due July 26, 2017

• ·         Independent investigators at or above the level of Assistant Professor (or equivalent)

• Fund highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care.

• ·         Optional Feature:  Applications that include a Qualified Collaborator who meets criteria identified in the announcement may apply for a higher level of funding.

·         Preliminary and/or published data required.

• ·         Clinical trials not allowed.

·         Maximum funding of $525,000 for direct costs (plus indirect costs)

·         Maximum funding of $575,000 for direct costs (plus indirect costs) for applications including an Optional Qualified Collaborator

• ·         Maximum period of performance is 3 years

 

New Investigator Award – Letter of Intent due July 26, 2017

• ·         Independent investigators at or below the level of Assistant Professor (or equivalent) or an established investigator at or above the level of Assistant Professor seeking to transition into a career in NF research

·         Support the continued development of promising independent investigators and/or the transition of established investigators into a career in the field of NF research

·         Experience in NF research is allowed, but not required

·         Preliminary and/or published data required

• ·         Clinical trials not allowed

·         Maximum funding of $450,000 for direct costs (plus indirect costs)

• ·         Maximum period of performance is 3 years

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released go to the CDMRP website (http://cdmrp.army.mil) and select Subscribe to Funding Opportunities & Program Communications.  For more information about the NFRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk

301-682-5507

help@eBrap.org

FY17 SCIRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

 

Clinical Research Development Award – Preproposal due August 8, 2017

Independent investigators at all academic levels (or equivalent)

·         Preproposal is required; application submission is by invitation only.

·         Fund research that will establish the necessary collaborations and develop the necessary research resources that will serve as a foundation for investigator-initiated clinical research.

• ·         Clinical trials not allowed.

·         Maximum funding of $100,000 for direct costs (plus indirect costs)

• ·         Maximum period of performance is 1 year

 

Clinical Trial Award – Preproposal due August 8, 2017

Independent investigators at all academic levels (or equivalent)

·         Preproposal is required; application submission is by invitation only.

• ·         Fund Phase 0, I, or II clinical trials with the potential to have a major impact on treatment or management of spinal cord injury (SCI) and its consequences.
• ·         Preclinical data required for all clinical trial applications.

·         Maximum funding of $2,000,000 for direct costs (plus indirect costs)

• ·         Maximum period of performance is 4 years

 

Investigator-Initiated Research Award – Preproposal due August 8, 2017

Independent investigators at all academic levels (or equivalent)

• ·         Preproposal is required; application submission is by invitation only.
• ·         Fund SCI-related research that has the potential to make an important contribution to SCI research and/or patient care.
• ·         Preliminary data required.
• ·         Clinical trials not allowed.
• ·         Maximum funding of $500,000 for direct costs (plus indirect costs)
• ·         Maximum period of performance is 3 years

 

Qualitative Research Award – Preapplication due August 8, 2017

Independent investigators at all academic levels (or equivalent)

·    Preproposal is required; application submission is by invitation only.

·    Fund qualitative research on military Service members and Veterans in the years following SCI.

·    Qualitative research is defined as a form of social inquiry that focuses on understanding the way that people interpret and make sense of their experiences and the world in which they live (i.e., seek to understand the human experience).

·    Preliminary data encouraged, but not required.

• ·   Clinical trials not allowed.

·      Maximum funding of $500,000 for direct costs (plus indirect costs)

• ·       Maximum period of performance is 3 years

Translational Research Award – Preproposal due August 8, 2017

Independent investigators at all academic levels (or equivalent)

·    Preproposal is required; application submission is by invitation only.

·    Fund studies that accelerate the movement of promising ideas in SCI research into clinical applications.

·    Optional Feature:  Applications that include a Qualified Collaborator that meets criteria identified in the announcement may apply for a higher level of funding.

·    Preliminary data required.

• ·       Limited clinical testing of a novel intervention or device is permissible.

·      Maximum funding of $1,250,000 for direct costs (plus indirect costs)

·      Maximum funding of $1,500,000 for direct costs (plus indirect costs) for applications including an Optional Qualified Collaborator

• ·       Maximum period of performance is 3 years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  .  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the SCIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org